Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

"It's been interesting to watch her trend down the growth chart to ... agonists for weight loss has grown, so too has their use in children. Currently, liraglutide and semaglutide are the only ...

So toss the weight chart ... semaglutide (Wegovy or Ozempic). Metformin. Metformin is primarily used to improve blood sugar regulation in those with type 2 diabetes, but it may also support weight ...

Ozempic (semaglutide) and Victoza (liraglutide ... Ozempic and Victoza are not approved for weight loss or weight management. However, some people using Ozempic and Victoza in studies did lose ...

Currently, semaglutide ... the bar graph on the right-hand side, you will see the pharmacodynamics of RT-114 measured by body weight. Both groups demonstrated an average peak weight loss of ...

Service GLP-1 Medication Platform Offering Affordable Access to Semaglutide, Tirzepatide, and Phentermine with 24/7 Coaching, ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.